In brief
Researchers are developing a mango-flavored pill that effectively targets intestinal worms, presenting a hopeful solution for a parasitic issue impacting 1.5 billion people worldwide, particularly children in developing countries.
A groundbreaking clinical trial has unveiled a mango-flavored pill that shows promising results in the fight against intestinal worms. This new medication combines existing anti-parasitic drugs for enhanced effectiveness and could potentially help eradicate parasitic infections that currently affect approximately 1.5 billion individuals worldwide, predominantly in developing nations where hygiene conditions are subpar.The combination pill targets soil-transmitted helminths (STHs), such as whipworm and hookworm, which are primarily contracted through contaminated food and water. These infections lead to severe gastrointestinal issues, malnutrition, and anemia, particularly among children. Researchers believe that the innovative pill could pave the way for large-scale disease management while also addressing concerns about future drug resistance.Dubbed "ALIVE," the study was published in the Lancet and signifies a major step toward achieving World Health Organization objectives for eliminating these diseases in heavily impacted regions. The treatment regimen involves administering either a single pill or three pills over consecutive days, offering a straightforward approach to mass treatment initiatives.Project leader Prof. Jose Muñoz emphasized the ease of administration with this new pill and expressed optimism that the dual-drug approach might lower the risk of developing drug-resistant parasites. Current treatments, such as albendazole, are becoming less effective against certain strains of STHs, necessitating alternative solutions.A clinical trial involving 1,001 children aged 5-18 across Ethiopia, Kenya, and Mozambique demonstrated that this combined treatment was more effective against various infections than when the drugs were used individually. Nevertheless, researchers noted inconclusive results regarding the pill's efficacy against threadworm.Despite the encouraging findings, experts like Prof. Hany Elsheikha from the University of Nottingham highlighted the study's limitations, urging caution since the current results may not extend to adults or populations outside the regions studied.Regulatory submissions for the trial results are underway in Europe and Africa, with decisions anticipated in early 2025. A follow-up trial is currently recruiting 20,000 participants in Kenya and Ghana, essential steps towards wide-spread implementation of this promising treatment.Dr. Stella Kepha from the Kenya Medical Research Institute remarked on the significant potential of the mango-flavored pill in improving the health of affected communities, while underlining the necessity for continued efforts to ensure successful rollout of the treatment.
